Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Molecular Characterization of Uropathogenic Escherichia coli Reveals Emergence of Drug Resistant O15, O22 and O25 Serogroups.

Prakapaite R, Saab F, Planciuniene R, Petraitis V, Walsh TJ, Petraitiene R, Semoskaite R, Baneviciene R, Kalediene L, Kavaliauskas P.

Medicina (Kaunas). 2019 Nov 11;55(11). pii: E733. doi: 10.3390/medicina55110733.

2.

Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis.

Petraitis V, Petraitiene R, Valdez JM, Pyrgos V, Lizak MJ, Klaunberg BA, Kalasauskas D, Basevicius A, Bacher JD, Benjamin DK Jr, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01626-19. doi: 10.1128/AAC.01626-19. [Epub ahead of print]

PMID:
31591128
3.

Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.

Petraitis V, Petraitiene R, Naing E, Aung T, Thi WP, Kavaliauskas P, Win Maung BB, Michel AO, Ricart Arbona RJ, DeRyke AC, Culshaw DL, Nicolau DP, Satlin MJ, Walsh TJ.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00344-19. doi: 10.1128/AAC.00344-19. Print 2019 Sep.

PMID:
31235620
4.

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.

Petraitis V, Petraitiene R, Maung BBW, Khan F, Alisauskaite I, Olesky M, Newman J, Mutlib A, Niu X, Satlin M, Singh RS, Derendorf H, Walsh TJ.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00275-18. doi: 10.1128/AAC.00275-18. Print 2018 Sep.

5.

Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

McCarthy MW, Moriyama B, Petraitiene R, Walsh TJ, Petraitis V.

Clin Pharmacokinet. 2018 Dec;57(12):1483-1491. doi: 10.1007/s40262-018-0673-2. Review.

PMID:
29725999
6.

Fungal Infections of the Central Nervous System in Children.

McCarthy MW, Kalasauskas D, Petraitis V, Petraitiene R, Walsh TJ.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e123-e133. doi: 10.1093/jpids/pix059. Review.

PMID:
28903523
7.

Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Petraitis V, Petraitiene R, McCarthy MW, Kovanda LL, Zaw MH, Hussain K, Shaikh N, Maung BBW, Sekhon NK, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00305-17. doi: 10.1128/AAC.00305-17. Print 2017 Sep.

8.

Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.

Petraitis V, Petraitiene R, Hope WW, Walsh TJ.

Methods Mol Biol. 2017;1625:259-277. doi: 10.1007/978-1-4939-7104-6_18.

PMID:
28584996
9.

Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses.

McCarthy MW, Petraitiene R, Walsh TJ.

Int J Mol Sci. 2017 May 24;18(6). pii: E1124. doi: 10.3390/ijms18061124. Review.

10.

Nucleic acid amplification methodologies for the detection of pulmonary mold infections.

McCarthy MW, Petraitiene R, Walsh TJ.

Expert Rev Mol Diagn. 2017 Mar;17(3):271-279. doi: 10.1080/14737159.2017.1293528. Review.

PMID:
28218019
11.

In vitro combination therapy with isavuconazole against Candida spp.

Katragkou A, McCarthy M, Meletiadis J, Hussain K, Moradi PW, Strauss GE, Myint KL, Zaw MH, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ, Petraitis V.

Med Mycol. 2017 Nov 1;55(8):859-868. doi: 10.1093/mmy/myx006.

PMID:
28204571
12.

Successful treatment of Aspergillus ventriculitis through voriconazole adaptive pharmacotherapy, immunomodulation, and therapeutic monitoring of cerebrospinal fluid (1→3)-β-D-glucan.

Chen TK, Groncy PK, Javahery R, Chai RY, Nagpala P, Finkelman M, Petraitiene R, Walsh TJ.

Med Mycol. 2017 Jan 1;55(1):109-117. Epub 2016 Nov 12. Review.

PMID:
27838641
13.

Entomophthoramycosis: a neglected tropical mycosis.

Shaikh N, Hussain KA, Petraitiene R, Schuetz AN, Walsh TJ.

Clin Microbiol Infect. 2016 Aug;22(8):688-94. doi: 10.1016/j.cmi.2016.04.005. Epub 2016 Apr 19. Review.

14.

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Kovanda LL, Petraitiene R, Petraitis V, Walsh TJ, Desai A, Bonate P, Hope WW.

J Antimicrob Chemother. 2016 Jul;71(7):1885-91. doi: 10.1093/jac/dkw098. Epub 2016 Apr 15.

15.

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Petraitis V, Petraitiene R, Moradi PW, Strauss GE, Katragkou A, Kovanda LL, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2718-26. doi: 10.1128/AAC.02665-15. Print 2016 May.

16.

Candida Arthritis: Analysis of 112 Pediatric and Adult Cases.

Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, Kontoyiannis DP, Roilides E, Zeller V, Taj-Aldeen SJ, Miller AO, Petraitiene R, Lortholary O, Walsh TJ.

Open Forum Infect Dis. 2015 Dec 23;3(1):ofv207. doi: 10.1093/ofid/ofv207. eCollection 2016 Jan.

17.

Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.

Petraitiene R, Petraitis V, Hope WW, Walsh TJ.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S643-51. doi: 10.1093/cid/civ817.

18.

Echinocandins: The Expanding Antifungal Armamentarium.

Aguilar-Zapata D, Petraitiene R, Petraitis V.

Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S604-11. doi: 10.1093/cid/civ814. Review.

PMID:
26567277
19.

(1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker for Candida and Aspergillus Infections of the Central Nervous System in Pediatric Patients.

Salvatore CM, Chen TK, Toussi SS, DeLaMora P, Petraitiene R, Finkelman MA, Walsh TJ.

J Pediatric Infect Dis Soc. 2016 Sep;5(3):277-86. doi: 10.1093/jpids/piv014. Epub 2015 Mar 19.

20.

Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.

Petraitiene R, Petraitis V, Bacher JD, Finkelman MA, Walsh TJ.

Med Mycol. 2015 Aug;53(6):558-68. doi: 10.1093/mmy/myv034. Epub 2015 Jun 30.

PMID:
26129890
21.

Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.

Al-Nakeeb Z, Petraitis V, Goodwin J, Petraitiene R, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2015 May;59(5):2735-45. doi: 10.1128/AAC.04723-14. Epub 2015 Feb 23.

22.

Quantitative multiplexed detection of common pulmonary fungal pathogens by labeled primer polymerase chain reaction.

Gu Z, Buelow DR, Petraitiene R, Petraitis V, Walsh TJ, Hayden RT.

Arch Pathol Lab Med. 2014 Nov;138(11):1474-80. doi: 10.5858/arpa.2013-0592-OA.

PMID:
25357108
23.

In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Katragkou A, McCarthy M, Meletiadis J, Petraitis V, Moradi PW, Strauss GE, Fouant MM, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6934-7. doi: 10.1128/AAC.03261-14. Epub 2014 Aug 18.

24.

Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.

Krel M, Petraitis V, Petraitiene R, Jain MR, Zhao Y, Li H, Walsh TJ, Perlin DS.

Antimicrob Agents Chemother. 2014 Jun;58(6):3373-8. doi: 10.1128/AAC.02482-14. Epub 2014 Mar 31.

25.

Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.

Such KA, Petraitis V, Petraitiene R, Strauss GE, Moradi PW, Walsh TJ.

J Am Assoc Lab Anim Sci. 2013 Sep;52(5):541-4.

26.
27.

Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism.

Petraitis V, Petraitiene R, Antachopoulos C, Hughes JE, Cotton MP, Kasai M, Harrington S, Gamaletsou MN, Bacher JD, Kontoyiannis DP, Roilides E, Walsh TJ.

Med Mycol. 2013 Jan;51(1):72-82. doi: 10.3109/13693786.2012.690107. Epub 2012 Jun 11.

PMID:
22686246
28.

Role of NADPH oxidase versus neutrophil proteases in antimicrobial host defense.

Vethanayagam RR, Almyroudis NG, Grimm MJ, Lewandowski DC, Pham CT, Blackwell TS, Petraitiene R, Petraitis V, Walsh TJ, Urban CF, Segal BH.

PLoS One. 2011;6(12):e28149. doi: 10.1371/journal.pone.0028149. Epub 2011 Dec 7.

29.

Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW.

Antimicrob Agents Chemother. 2012 Feb;56(2):708-14. doi: 10.1128/AAC.05826-11. Epub 2011 Nov 28.

30.

Galactomannan antigenemia after infusion of gluconate-containing Plasma-Lyte.

Petraitiene R, Petraitis V, Witt JR 3rd, Durkin MM, Bacher JD, Wheat LJ, Walsh TJ.

J Clin Microbiol. 2011 Dec;49(12):4330-2. doi: 10.1128/JCM.05031-11. Epub 2011 Oct 5.

31.

Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.

Walsh TJ, Wissel MC, Grantham KJ, Petraitiene R, Petraitis V, Kasai M, Francesconi A, Cotton MP, Hughes JE, Greene L, Bacher JD, Manna P, Salomoni M, Kleiboeker SB, Reddy SK.

J Clin Microbiol. 2011 Dec;49(12):4150-7. doi: 10.1128/JCM.00570-11. Epub 2011 Oct 5.

32.

Early serum (1→3)-β-D-glucan levels in patients with burn injury.

Shupp JW, Petraitiene R, Jaskille AD, Pavlovich AR, Matt SE, Nguyen do T, Kath MA, Jeng JC, Jordan MH, Finkelman M, Walsh TJ, Shoham S.

Mycoses. 2012 May;55(3):224-7. doi: 10.1111/j.1439-0507.2011.02068.x. Epub 2011 Jul 19.

PMID:
21771107
33.

Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia.

Gonzales DA, De Torre C, Wang H, Devor CB, Munson PJ, Ying SX, Kern SJ, Petraitiene R, Levens DL, Walsh TJ, Suffredini AF.

Proteomics. 2010 Dec;10(23):4270-80. doi: 10.1002/pmic.200900768.

34.

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2010 Nov;54(11):4879-86. doi: 10.1128/AAC.00673-10. Epub 2010 Aug 16.

35.

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.

Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2009 Jun;53(6):2382-91. doi: 10.1128/AAC.00329-09. Epub 2009 Mar 23.

36.

Diagnostic imaging of experimental invasive pulmonary aspergillosis.

Walsh TJ, Petraitis V, Petraitiene R, Solomon J, Bacher JD, Greene L, Cotton M, Groll A, Roilides E, Avila N, Pyrgos V, Shoham S.

Med Mycol. 2009;47 Suppl 1:S138-45. doi: 10.1080/13693780802665879. Epub 2009 Feb 27. Review.

PMID:
19253145
37.

Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis.

Kasai M, Harrington SM, Francesconi A, Petraitis V, Petraitiene R, Beveridge MG, Knudsen T, Milanovich J, Cotton MP, Hughes J, Schaufele RL, Sein T, Bacher J, Murray PR, Kontoyiannis DP, Walsh TJ.

J Clin Microbiol. 2008 Nov;46(11):3690-702. doi: 10.1128/JCM.00917-08. Epub 2008 Sep 24.

38.

Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis.

Petraitiene R, Petraitis V, Hope WW, Mickiene D, Kelaher AM, Murray HA, Mya-San C, Hughes JE, Cotton MP, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2008 Nov;52(11):4121-9. doi: 10.1128/AAC.00674-08. Epub 2008 Sep 8.

39.

Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis.

Hayden R, Pounds S, Knapp K, Petraitiene R, Schaufele RL, Sein T, Walsh TJ.

Pediatr Infect Dis J. 2008 Sep;27(9):815-9. doi: 10.1097/INF.0b013e31817197ab.

PMID:
18703991
40.

Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR.

Francesconi A, Kasai M, Harrington SM, Beveridge MG, Petraitiene R, Petraitis V, Schaufele RL, Walsh TJ.

J Clin Microbiol. 2008 Jun;46(6):1978-84. doi: 10.1128/JCM.02246-07. Epub 2008 Mar 19.

41.

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK Jr, Groll AH, Drusano GL, Walsh TJ.

J Infect Dis. 2008 Jan 1;197(1):163-71. doi: 10.1086/524063.

42.

Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay.

De Jesus M, Hackett E, Durkin M, Connolly P, Casadevall A, Petraitiene R, Walsh TJ, Wheat LJ.

Clin Vaccine Immunol. 2007 May;14(5):624-7. Epub 2007 Mar 14.

43.

Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay.

Wheat LJ, Hackett E, Durkin M, Connolly P, Petraitiene R, Walsh TJ, Knox K, Hage C.

Clin Vaccine Immunol. 2007 May;14(5):638-40. Epub 2007 Mar 7.

44.

Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ.

J Infect Dis. 2007 Feb 1;195(3):455-66. Epub 2006 Dec 21.

PMID:
17205486
45.

Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2006 Oct;50(10):3418-23.

46.

Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.

Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, Sein T, Schaufele RL, Bacher J, Walsh TJ.

J Infect Dis. 2006 Oct 1;194(7):1008-18. Epub 2006 Aug 28.

PMID:
16960790
47.
48.

Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.

Petraitis V, Petraitiene R, Solomon J, Kelaher AM, Murray HA, Mya-San C, Bhandary AK, Sein T, Avila NA, Basevicius A, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2006 Apr;50(4):1510-7.

49.
50.

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH.

Antimicrob Agents Chemother. 2006 Feb;50(2):422-7.

Supplemental Content

Loading ...
Support Center